Physiology of Interregional Connectivity in the Human Brain

Healthy Clinical Trial

Official title:

Physiology of Interregional Connectivity in the Human Brain

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03723434
• Other study ID #: STU00204239
• Status: Recruiting
• Phase: N/A
• Start date: May 31, 2017
• Est. completion date: November 2020

Study information

• Verified date: October 2018
• Source: Shirley Ryan AbilityLab
• Contact: Tommi Raij, MD, PhD
• Phone: 312-238-4401
• Email: tommi.raij[@]northwestern.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to understand the physiology of connectivity between cortical regions in the human brain in healthy participants and in patients with white matter lesions. Specifically, the investigators will examine the effects of paired associative stimulation (PAS) which consists in delivering brief (< 1 ms) current pulses separated by a short millisecond-level time interval ("asynchrony") to two cortical areas. The used techniques are all non-invasive and considered safe in humans: transcranial magnetic stimulation (TMS), electroencephalography (EEG), magnetic resonance imaging (MRI), and functional MRI (fMRI). Based on prior literature in animals and human studies, it is hypothesized that PAS may increase or decrease effective connectivity between the stimulated areas depending on the asynchrony value. The main outcome measure is source-resolved EEG responses evoked by single-pulse TMS; this is a more direct measure of neuronal changes occurring at the targeted cortical area than motor evoked potentials (MEPs) or sensor-level EEG responses used in previous studies.

Description:

This study consists of two experiments.

In Experiment A, healthy participants without disorders or medications influencing brain function (N=24) will be recruited. A range of negative and positive asynchronies (from minus 50 to + 50 ms) will be tested. To allow comparison with prior studies that used MEPs as outcome measures, in 12 participants the primary motor cortex in the left and right hemisphere will be targeted. In another 12 participants, two cortical areas within the same hemisphere will be stimulated.

In Experiment B, participants with stroke, traumatic brain injury (TBI), or multiple sclerosis (MS) (total maximum N across all such participants is 52) will be recruited. These participants are required to have one or more subcortical white matter lesions, which would be expected to result in cortico-cortical disconnections. Here, the investigators will only test PAS with positive asynchronies, with the goal of testing if the findings observed in healthy participants are similar in participants with white matter lesions. It will also be examined if the PAS-induced connectivity changes persist beyond the stimulation sessions if PAS is given repeatedly over several days. PAS will be applied to two cortical targets that have been disconnected from each other. The rationale for including more than one disorder in Experiment B is that the disconnections are in all cases caused by white matter lesions and the results may therefore be similar. To detect possible differences between disorders, the data from the three groups will also be analyzed separately.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 76
• Est. completion date: November 2020
• Est. primary completion date: November 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

Inclusion Criteria for Healthy Participants:

• Age from 18 to 85 years

• Right-handed

• Normal hearing and (corrected) vision

• Able to understand and give informed consent

• English speaker

Inclusion Criteria for Patients:

• Age from 18 to 85 years

• Stroke (ischemic subcortical, intermediate level, chronic phase 3 weeks or more from lesion)

• TBI (closed-skull, intermediate level, chronic phase 3 weeks or more from lesion)

• MS (white matter subcortical lesion)

• Clinical and radiological evidence supporting the above diagnoses

• One or more behavioral symptoms possibly linked to the white matter lesion(s)

• Stable medical condition

• English speaker

Exclusion Criteria:

Exclusion Criteria for Healthy Participants:

• Cardiac pacemaker or pacemaker wires; neurostimulators; implanted pumps

• Metal in the body (rods, plates, screws, shrapnel, dentures, IUD) or metallic particles in the eye

• Surgical clips in the head or previous neurosurgery

• Any magnetic particles in the body

• Cochlear implants

• Prosthetic heart valves

• Epilepsy or any other type of seizure history

• Any neurological diagnoses or medications influencing brain function

• History of significant head trauma (i.e., extended loss of consciousness, neurological sequelae)

• Known structural brain lesion

• Significant other disease (heart disease, malignant tumors, mental disorders)

• Significant claustrophobia; Ménière's disease

• Pregnancy (ruled out by urine ß-HCG if answers to screening questions suggest that pregnancy is possible), breast feeding

• Non prescribed drug use

• Failure to perform the behavioral tasks or neuropsychological evaluation tests

• Prisoners

Exclusion Criteria for Patients:

• Same as above, excluding the requirement of no structural brain lesion, and medications influencing brain function are allowed

• Patients with cortical lesions or CSF-filled cysts/cavities near the TMS sites

• MS patients with acute exacerbation

Related Conditions & MeSH terms

• Brain Injuries
• Brain Injuries, Traumatic
• Healthy
• Multiple Sclerosis
• Sclerosis
• Stroke
• Traumatic Brain Injury

Intervention

Device:
• Single-pulse transcranial magnetic stimulation (spTMS)
Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
• Paired associative stimulation (PAS)
Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, St Augustin, Germany).
• Repetitive transcranial magnetic stimulation (rTMS)
Repetitive TMS (rTMS) will be applied at 1 and 20 Hz with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 300 rTMS pulses will be delivered during 1 and 20 Hz stimulation. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).

Locations

Country	Name	City	State
United States	Shirley Ryan AbilityLab	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
Shirley Ryan AbilityLab	Northwestern University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in EEG effective connectivity	EEG will be recorded with a 64-channel whole-head TMS-compatible device (NeurOne, Bittium, Kuopio, Finland). Data will be collected before (Pre-PAS) and at 1 minute (Post-PAS T1) and at 60 minutes (Post-PAS T60) after PAS. To record spTMS-evoked EEG responses the investigators will deliver 80 single TMS pulses to the two areas receiving PAS, one target after the other in separate runs. Effective connectivity will be measured by comparing the source-resolved EEG evoked response waveforms before (Pre-PAS) and at 1 (Post-PAS T1) and at 60 minutes after PAS (Post-PAS T60).	Experiment A: Within-session (before versus after PAS at 1 and 60 minutes). Experiment B: Within-session (before versus after PAS at 1 and 60 minutes). Across-sessions (persistence of changes up to 1 month after last PAS session).
Primary	Changes in resting-state EEG coherence	Resting-state EEG will be recorded with a 64-channel whole-head device (NeurOne, Bittium, Kuopio, Finland). Data will be collected before (Pre-PAS) and at 1 minute (Post-PAS T1) and at 60 minutes (Post-PAS T60) after PAS. Resting-state EEG coherence will be computed in the source space for the two areas receiving PAS from 1 to 100 Hz.	Experiment A: Within-session (before versus after PAS at 1 and 60 minutes). Experiment B: Within-session (before versus after PAS at 1 and 60 minutes). Across-sessions (persistence of changes up to 1 month after last PAS session).
Secondary	Motor evoked potentials (MEPs)	To assess the effects of PAS in participants where the primary motor cortex (M1) was targeted, spTMS will be administered to the M1 at 110% of resting motor threshold (rMT) while MEPs are recorded from the contralateral hand (NeurOne, Bittium, Kuopio, Finland). The MEPs will be recorded before (Pre-PAS), at 1 minute (Post-PAS T1) and at 60 minutes (Post-PAS T60) after PAS.	Experiment A: Within-session (before versus after PAS at 1 and 60 minutes). Experiment B: Done only in patients where the M1 was targeted with PAS.
Secondary	MRI functional connectivity	Functional connectivity will be assessed with resting-state MRI (rs-MRI).	Experiment A: Baseline. Experiment B: Baseline to 1 month after the last PAS session.
Secondary	MRI structural connectivity	Structural connectivity will be assessed with diffusion tensor imaging (DTI).	Experiment A: Baseline. Experiment B: Baseline to 1 month after the last PAS session.